The traditional approach to process validation, once viewed as a one-time "three-batch" hurdle, has undergone a fundamental shift toward a science-based, lifecycle approach. This new paradigm, championed by the ISPE and regulatory bodies like the FDA, emphasizes that quality cannot be tested into a product; it must be built in by design. The Lifecycle Framework
This shift from "snapshots" to "continuous oversight" offers significant benefits:
The New Process Validation Paradigm represents a move toward a more "proactive" pharmaceutical quality system. By treating validation as an ongoing journey rather than a destination, the industry ensures a more reliable supply of safe, effective medicines for patients. The New Process Validation Paradigm - ISPE Bost...
This stage replaces the rigid "three-batch" rule. Instead, the number of batches is determined by risk assessment and statistical confidence. It confirms that the process design is capable of reproducible commercial manufacturing.
The focus here is on building a deep understanding of the product and process. By identifying Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) early on, manufacturers can establish a "Design Space" where quality is guaranteed through scientific rationale rather than luck. The traditional approach to process validation, once viewed
It aligns with ICH Q8, Q9, and Q10 guidelines, facilitating smoother inspections and global compliance. Conclusion
Early identification of variability prevents costly batch failures. By treating validation as an ongoing journey rather
The new paradigm is structured into three distinct stages that move away from static documentation toward continuous learning: